Skip to content
Who We Serve
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees
About Us
Our Team
Our Story
Investment Strategies
Who We Serve
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees
About Us
Our Team
Our Story
Investment Strategies
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees (911 Financial Services™)
Our Story
Our Team
Investment Strategies
Contact Us
Schwab Client Login
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees (911 Financial Services™)
Our Story
Our Team
Investment Strategies
Contact Us
Schwab Client Login
Contact Us
Schwab Client Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Taysha Gene Therapies, Inc. - Common Stock
(NQ:
TSHA
)
3.930
-0.130 (-3.20%)
Delayed Quote
Updated: 10:54 AM EST, Nov 17, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Taysha Gene Therapies, Inc. - Common Stock
< Previous
1
2
3
Next >
Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update
November 12, 2026
From
Taysha Gene Therapies, Inc.
Via
GlobeNewswire
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 06, 2026
From
Taysha Gene Therapies, Inc.
Via
GlobeNewswire
Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12
November 05, 2026
From
Taysha Gene Therapies, Inc.
Via
GlobeNewswire
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2026
From
Taysha Gene Therapies, Inc.
Via
GlobeNewswire
Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting
October 01, 2026
From
Taysha Gene Therapies, Inc.
Via
GlobeNewswire
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 04, 2026
From
Taysha Gene Therapies, Inc.
Via
GlobeNewswire
Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 11, 2026
From
Taysha Gene Therapies, Inc.
Via
GlobeNewswire
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 07, 2026
From
Taysha Gene Therapies, Inc.
Via
GlobeNewswire
Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11
August 04, 2026
From
Taysha Gene Therapies, Inc.
Via
GlobeNewswire
Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
August 03, 2026
From
Taysha Gene Therapies, Inc.
Via
GlobeNewswire
Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting
June 25, 2026
From
Taysha Gene Therapies, Inc.
Via
GlobeNewswire
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
June 24, 2026
From
Taysha Gene Therapies, Inc.
Via
GlobeNewswire
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
June 24, 2026
From
Taysha Gene Therapies, Inc.
Via
GlobeNewswire
Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome
June 22, 2026
From
Taysha Gene Therapies, Inc.
Via
GlobeNewswire
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 05, 2026
From
Taysha Gene Therapies, Inc.
Via
GlobeNewswire
Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 06, 2026
From
Taysha Gene Therapies, Inc.
Via
GlobeNewswire
Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6
April 29, 2026
From
Taysha Gene Therapies, Inc.
Via
GlobeNewswire
Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting
April 27, 2026
From
Taysha Gene Therapies, Inc.
Via
GlobeNewswire
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 03, 2026
From
Taysha Gene Therapies, Inc.
Via
GlobeNewswire
Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update
March 19, 2026
From
Taysha Gene Therapies, Inc.
Via
GlobeNewswire
Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19
March 12, 2026
From
Taysha Gene Therapies, Inc.
Via
GlobeNewswire
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2026
From
Taysha Gene Therapies, Inc.
Via
GlobeNewswire
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 06, 2026
From
Taysha Gene Therapies, Inc.
Via
GlobeNewswire
Taysha Gene Therapies (NASDAQ: TSHA) Receives $50 Million Strategic Investment From Astellas Pharma to Develop AAV-Based Gene Therapeutics
October 25, 2022
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) is a biotechnology company that is focused on developing gene therapies to treat monogenic
Via
Spotlight Growth
Taysha Gene Therapies Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 31, 2022
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-102 in Rett Syndrome
March 29, 2022
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Taysha Gene Therapies to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 31
March 24, 2022
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Taysha Gene Therapies to Participate in Upcoming April Investor Healthcare Conferences
March 23, 2022
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Taysha Gene Therapies Announces Positive Safety Data from UT Southwestern-Sponsored Clinical Trial for the Treatment of CLN7 Batten Disease at 18th Annual WORLDSymposium
February 09, 2022
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Taysha Gene Therapies Reports Positive Clinical Efficacy and Safety Data for High Dose Cohort and Long-term Durability Data for TSHA-120 in Giant Axonal Neuropathy
January 31, 2022
From
Taysha Gene Therapies, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.